Literature DB >> 32399910

Short-form RON (sf-RON) enhances glucose metabolism to promote cell proliferation via activating β-catenin/SIX1 signaling pathway in gastric cancer.

Ziliang Wang1,2, Yufei Yang3, Shuang Hu4, Jian He5, Zheng Wu5,6, Zihao Qi7, Mingzhu Huang5,6, Rujiao Liu5,6, Ying Lin5,6, Cong Tan6,8,9, Midie Xu10,11,12, Zhe Zhang13,14.   

Abstract

Recepteur d'origine nantais (RON) has been implicated in cell proliferation, metastasis, and chemoresistance of various human malignancies. The short-form RON (sf-RON) encoded by RON transcripts was overexpressed in gastric cancer tissues, but its regulatory functions remain illustrated. Here, we found that sf-RON promoted gastric cancer cell proliferation by enhancing glucose metabolism. Furthermore, sf-RON was proved to induce the β-catenin expression level through the AKT1/GSK3β signaling pathway. Meanwhile, the binding sites of β-catenin were identified in the promoter region of SIX1 and it was also demonstrated that β-catenin positively regulated SIX1 expression. SIX1 enhanced the promoter activity of key proteins in glucose metabolism, such as GLUT1 and LDHA. Results indicated that sf-RON regulated the cell proliferation and glucose metabolism of gastric cancer by participating in a sf-RON/β-catenin/SIX1 signaling axis and had significant implications for choosing the therapeutic target of gastric cancer.

Entities:  

Keywords:  Gastric cancer; Glucose metabolism; SIX1; sf-RON; β-Catenin

Mesh:

Substances:

Year:  2020        PMID: 32399910      PMCID: PMC7851020          DOI: 10.1007/s10565-020-09525-5

Source DB:  PubMed          Journal:  Cell Biol Toxicol        ISSN: 0742-2091            Impact factor:   6.691


  49 in total

Review 1.  RON Signaling Is a Key Mediator of Tumor Progression in Many Human Cancers.

Authors:  Najme Faham; Alana L Welm
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2017-01-05

2.  RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE.

Authors:  Sreedhar Reddy Suthe; Hang-Ping Yao; Tian-Hao Weng; Chen-Yu Hu; Liang Feng; Zhi-Gang Wu; Ming-Hai Wang
Journal:  Mol Cancer Ther       Date:  2018-10-01       Impact factor: 6.261

3.  Resistance to chemotherapy is associated with altered glucose metabolism in acute myeloid leukemia.

Authors:  Kui Song; Min Li; Xiaojun Xu; L I Xuan; Guinian Huang; Qifa Liu
Journal:  Oncol Lett       Date:  2016-05-17       Impact factor: 2.967

4.  Transcriptional Regulation of the Warburg Effect in Cancer by SIX1.

Authors:  Ling Li; Yingchun Liang; Lei Kang; Yang Liu; Shan Gao; Siyu Chen; Ying Li; Wenye You; Qian Dong; Tian Hong; Zhifeng Yan; Shuai Jin; Tao Wang; Wei Zhao; Haixing Mai; Jun Huang; Xiao Han; Quanbo Ji; Qi Song; Chao Yang; Shixin Zhao; Xiaojie Xu; Qinong Ye
Journal:  Cancer Cell       Date:  2018-02-15       Impact factor: 31.743

Review 5.  Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets.

Authors:  Katherine Chang; Anand Karnad; Shujie Zhao; James W Freeman
Journal:  Oncotarget       Date:  2015-02-28

6.  Short-form Ron is a novel determinant of ovarian cancer initiation and progression.

Authors:  Katherine M Moxley; Luyao Wang; Alana L Welm; Magdalena Bieniasz
Journal:  Genes Cancer       Date:  2016-05

7.  A novel RON splice variant lacking exon 2 activates the PI3K/AKT pathway via PTEN phosphorylation in colorectal carcinoma cells.

Authors:  Yu Ling; Yeye Kuang; Lin-Lin Chen; Wei-Feng Lao; Yao-Ru Zhu; Le-Qi Wang; Da Wang
Journal:  Oncotarget       Date:  2017-06-13

8.  Targeting autophagy potentiates antitumor activity of Met-TKIs against Met-amplified gastric cancer.

Authors:  Xiaoting Lin; Zhi Peng; Xiaojuan Wang; Jianling Zou; Dongshao Chen; Zuhua Chen; Zhongwu Li; Bin Dong; Jing Gao; Lin Shen
Journal:  Cell Death Dis       Date:  2019-02-13       Impact factor: 8.469

9.  Metabolic tumor burden on postsurgical PET/CT predicts survival of patients with gastric cancer.

Authors:  Gaofeng Sun; Chao Cheng; Xiao Li; Tao Wang; Jian Yang; Danni Li
Journal:  Cancer Imaging       Date:  2019-03-22       Impact factor: 3.909

10.  Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer.

Authors:  Zheng Wu; Zhe Zhang; Xiaoxiao Ge; Ying Lin; Congqi Dai; Jinjia Chang; Xinyang Liu; Ruixuan Geng; Chenchen Wang; Huan Chen; Menghong Sun; Weijian Guo; Jin Li
Journal:  Oncotarget       Date:  2015-12-01
View more
  1 in total

Review 1.  The MST1R/RON Tyrosine Kinase in Cancer: Oncogenic Functions and Therapeutic Strategies.

Authors:  Alex Cazes; Betzaira G Childers; Edgar Esparza; Andrew M Lowy
Journal:  Cancers (Basel)       Date:  2022-04-18       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.